Latest News

: J&J: ‘Tripledemic’ fueled demand for Motrin and Tylenol

0

As cases of COVID, flu and respiratory syncytial virus, or RSV, surged in the fall as part of a “tripledemic” in the U.S., demand for cold medications translated to a good quarter for Johnson & Johnson’s JNJ consumer health business.

J&J’s over-the-counter division, which includes the pain reliever Motrin and the allergy medicine Zyrtec, had sales of $1.57 billion in the final three months of 2022, up from $1.37 billion in the same quarter of the previous year. It also beat the FactSet consensus of $1.4 billion. (The company…

Jonathan Burton’s Life Savings: ‘The Nasdaq is our favorite short.’ This market strategist sees recession and a credit crunch slamming stocks in 2023.

Previous article

Market Extra: NYSE says ‘system issue’ led to glitch that caused dozens of trading halts, wild price swings on open

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News